Skip to main content

Recombinant Human CD84/SLAMF5 Protein

R&D Systems, part of Bio-Techne | Catalog # 1855-CD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
1855-CD-050/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
1855-CD-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human CD84/SLAMF5 protein
Lys22-Arg220, with a C-terminal 10-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Lys22

Predicted Molecular Mass

23.6 kDa

SDS-PAGE

40-43 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using PHA stimulated human T cells in the presence of anti-CD3. Tangye, S.G. et al. (2003) J. Immunol. 171:2485.
The ED50 for this effect is 1-4 μg/mL in the presence of anti-CD3 immobilized at least at 20 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 1855-CD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 1855-CD/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD84/SLAMF5

CD84, also known as Ly-9B and SLAMF5, is a type I transmembrane protein in the SLAM subgroup of the CD2 family. SLAM family proteins regulate multiple aspects of immune system function (1). Mature human CD84 consists of a 204 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 99 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs (ITSMs) (2, 3). Alternate splicing generates a soluble ECD, an isoform that lacks the first Ig-like domain, and additional isoforms with deletions in the cytoplasmic domain (4). CD84 exhibits homophilic binding which is mediated by the N-terminal Ig-like domain (5). Ligation induces tyrosine phosphorylation in the cytoplasmic ITSMs which then recruit the signaling adaptor molecules SAP (SLAM-associated protein) and EAT-2 (EWS/Fli1-activated transcript 2) (6, 7). CD84 is expressed as a 60-90 kDa molecule with extensive and cell type-specific glycosylation (2, 3, 8). It is widely expressed among hematopoietic cells including hematopoietic stem cells (8), myeloid cells (e.g. macrophages, monocytes, dendritic cells, granulocytes, and mast cells) (3, 6, 8‑10), platelets and megakaryocytes (3, 5, 8, 11), and lymphocytes. Within the T cell lineage, CD84 is expressed on thymocytes, CD4-CD8- cells, single positive CD4 or CD8 cells, NKT cells, and on mouse but not human NK cells (5, 6, 8, 9, 12). Within the B cell lineage, it is expressed on pro- and pre-, mature, marginal zone, and memory B cells as well as plasma cells (6, 8, 13). CD84 signaling inhibits Fc epsilon RI-induced mast cell activation (10) but enhances platelet activation (11), LPS-induced macrophage activation (8), T cell proliferation and IFN-gamma production (5, 7), and the interactions between T cells and B cells that are required for germinal center formation (14).

References

  1. Cannons, J.L. et al. (2011) Annu. Rev. Immunol.  29:665.
  2. de la Fuente, M.A. et al. (1997) Blood. 90:2398.
  3. Krause, S.W. et al. (2000) Biochem. J. 346:729.
  4. Palou, E. et al. (2000) Tissue Antigens 55:118.
  5. Martin, M. et al. (2000) J. Immunol. 167:3668.
  6. Tangye, S.G. et al. (2002) Eur. J. Immunol. 32:1640.
  7. Tangye, S.G. et al. (2003) J. Immunol. 171:2485.
  8. Sintes, J. et al. (2010) J. Leukoc. Biol. 88:687.
  9. Romero, X. et al. (2004) Tissue Antigens 64:132.
  10. Alvarez-Errico, D. et al. (2011) J. Immunol. 187:5577.
  11. Nanda, N. et al. (2005) Blood 106:3028.
  12. Wang, N. et al. (2010) J. Immunol. 185:5683.
  13. De Salort, J. et al. (2011) Immunol. Lett. 134:129.
  14. Cannons, J.L. et al. (2010) Immunity 32:253.

Long Name

SLAM Family Member 5

Alternate Names

CD84, Ly-9B, SLAMF5

Entrez Gene IDs

8832 (Human); 12523 (Mouse)

Gene Symbol

CD84

UniProt

Additional CD84/SLAMF5 Products

Product Documents for Recombinant Human CD84/SLAMF5 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CD84/SLAMF5 Protein

For research use only

Loading...
Loading...
Loading...